AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nodsFiercepharma·Nov 16, 2026 at 03:43 PMAZN-0.05%AZN
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europebenzinga_article·Nov 16, 2026 at 12:52 PMAZN-0.05%AZNCF
China Adds Record 51 Innovative Drugs to Public Medical Insurance CatalogYicai·Nov 16, 2026 at 11:44 AMAZN-0.05%NVO+0.04%
Sofinnova Partners backs European life sciences sector with €725M raisePharmaceutical Technology·Nov 16, 2026 at 09:53 AMABVX-3.57%AHKSY-1.70%
AstraZeneca secures FDA approval for Imfinzi combo in MIBCPharmaceutical Technology·Nov 16, 2026 at 09:37 AMAZN-0.05%AZN
AstraZeneca: Alexion's Klygefa Gets EU Approval To Treat Adults With Generalised Myasthenia Gravisrttnews·Nov 16, 2026 at 07:45 AMAZN-0.05%AZN
REG - AstraZeneca PLC - Baxfendy recommended for approval in the EULondon Stock Exchange·Nov 16, 2026 at 07:15 AMAZN-0.05%AZN
Weekly Recap | AstraZeneca -1.06%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 06:02 AMAZN-0.05%
Is AstraZeneca (LSE:AZN) Still Cheap After Its 83% Five Year Run?Simplywall·Nov 14, 2026 at 01:07 AMAZN-0.05%AZN
AstraZeneca rises 4% in after-hours on positive EU opinion for BaxfendyMarket Movers·Nov 13, 2026 at 11:41 PMAZN-0.05%
AstraZeneca (AZN) Wins FDA Approval for IMFINZI Bladder Cancer RegimenTradingView·Nov 13, 2026 at 11:39 PMAZN-0.05%AZN
AstraZeneca's Baxfendy wins EU panel backing for hypertension treatmentPUBT·Nov 13, 2026 at 11:47 AMAZN-0.05%AZN
Nine Listings Transfer to the NYSE in 2026 Amounting to $500B in Market Cap | ICE Stock NewsStockTitan·Nov 12, 2026 at 09:45 AMAZN-0.05%CRTO+4.46%